AANS Neurosurgeon | Volume 26, Number 1, 2017


Study Shows Potential for New Glioblastoma Treatment

Bookmark and Share

A completely new treatment for glioblastoma, which combines a common chemotherapy agent with T cells, may enter clinical trials following highly successful mouse-model studies. Researchers with the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles reported in the journal Neuro-Oncology that this new hybrid treatment has successfully passed all animal studies and is being considered for clinical trials in humans due to its apparent lower risks combined with improved outcomes. The treatment is recommended for fast-growing tumors following surgery in order to prevent the highly common relapses found following glioblastoma removals. “By treating glioblastoma cells with decitabine, we found that we can unmask targets on the tumor cell that can be recognized by killer T cells,” he adds. “Once these targets are uncovered, we can then administer T cells that are genetically programmed to attack tumor cells with the new targets.” To learn more about this study, click here.


Microsurgery Course Zurich
March 29-April 1, 2017; Zurich, Switzerland

12th World Congress on Brain Injury
March 29-April 1, 2017; New Orleans

2017 National Neuroscience Review
March 31-April 1, 2017; National Harbor, Md.

Brain & Brain PET 2017
April 1-4, 2017; Berlin, Germany

Neurosurgical Society of America Annual Meeting 2017
April 2-5, 2017; Jacksonville, Fla.

Interactive Calendar

Comments are closed.